 Hi, my name is Neelam Malia and I'm working as an assistant professor at the Department of Microbiology and Immunology at the Roslyn Franklin Institute. And recently I started working on the inflammatory breast cancer, especially the inflammation part and the tumor microenvironment. And I was lucky to have a graduate student in my lab, she did a lot of work on deciphering the role of various proteins secreted in the microenvironment of the inflammatory breast cancer cells. And her name is Sudeshna Goswami, she published a lot and we have two manuscripts in Angotarget and we have also a review article in Angotarget and she's going to summarize her findings in the work that she did. Hello everyone, I'm Sudeshna Goswami and I've worked on breast cancer and inflammatory and invasive two different kinds of breast cancer and the protein that I'm interested in is osteoprotegrin that we talk about in the review article. And when I started working on breast cancer I found that this protein gets secreted in very high amounts in the secretion, the tumor microenvironment of such breast cancer whereas you see no deductible levels in the control primary epithelial cell which is a normal mammary cell. And that got us very interested because back in 1889 as Stephen Page had said tumor microenvironment and cancer is like the seed and the soil and there is a very close relation. And because with a lot of PubMed search we figured out that much hasn't been talked about this protein apart from the fact that it induced angiogenesis and that secretion is correlated with very aggressive behavior in different forms of cancer, not just breast cancer, we wanted to delve deeper and that's how we started, I started working on this protein, figured out a lot of different functional activities apart from confirming the fact that it does induce angiogenesis we figured out that it induces a lot of pateocrine activities of this protein, let me tell you. So we found that this protein has the capacity to induce high proliferation in normal mammary epithelial cell, you know, in a in a sphere culture which is a 3D culture which is mimicking the in vivo tumor a lot. You take the complexity and notch higher with the 3D culture. And apart from increasing proliferation we do see cell cycle aberration. Very interesting finding is the onset of aneuploidy and a pregulation of the CD24 marker, CD24 and not that much in CD44 cell surface receptors. And to correlate with the onset of aneuploidy which has never been talked about before, we also show that this is because the change or aberration in the copy number variants that is induced when you culture the normal cells just in presence of this recombinant protein. And we kind of extrapolated and we found that this is the scenario is very much similar to what you observe in inflammatory breast cancer patient sample. And apart from that we took it further because the lab also works on the COX2PG to inflammatory pathway and nothing much was talked about between osteoprotegrin and COX2PG to pathway apart from with respect to bone. We also got interested into that and we found that the crosstalk between there is a possible crosstalk between osteoprotegrin and COX2PG to via the FASN, which is also published in OncoTarget recently. And this research definitely opened a lot of avenues for combinatorial treatment like targeting COX2PG2 with selicoxa, which is already in clinical trial. And also you can target FASN with C75 or any other drug. And nowadays apart from like single therapy, combinatorial therapy is a lot more in bulk. And not just that because osteoprotegrin gets secreted at very high levels, it can also be used as an easy biomarker for detection of the aggressiveness of the disease. So there are a lot of papers like and we also found that osteoprotegrin interacts with one of the receptors. It's a nucleolin and our lab is also working on that. And we are expanding and trying to figure out more of this interacting network that goes on with osteoprotegrin and the other inflammatory pathways. So a lot more will be coming up from the lab. So if you're interested, go to PubMed. You can look up with my name and Dr. Walia's name or just type in osteoprotegrin. And keep an eye out because a lot more research is coming your way.